Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
$0.66
$0.74
$0.55
$4.56
$16.15MN/AN/A574,675 shs
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
$0.37
+1.5%
$0.39
$0.30
$10.62
$52.27M1.863.39 million shs1.19 million shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$2.43
+13.0%
$2.04
$1.14
$11.16
$75.27M1.69374,247 shs342,900 shs
Exicure, Inc. stock logo
XCUR
Exicure
$10.80
+9.1%
$10.82
$1.44
$36.00
$68.23M3.71561,064 shs7,022 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
0.00%0.00%0.00%0.00%0.00%
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
+1.48%+3.30%-10.39%-35.50%-91.64%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
+12.94%+21.87%+33.79%-7.41%-78.95%
Exicure, Inc. stock logo
XCUR
Exicure
+9.09%+10.54%+8.32%-6.90%+2,060.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
3.8018 of 5 stars
3.31.00.04.72.71.70.6
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1.0951 of 5 stars
3.52.00.00.00.60.00.0
Exicure, Inc. stock logo
XCUR
Exicure
0.6963 of 5 stars
0.03.00.04.70.00.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
0.00
N/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
2.50
Moderate Buy$6.101,552.22% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00
Buy$16.60583.13% Upside
Exicure, Inc. stock logo
XCUR
Exicure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ACER, APLT, XCUR, and SKYE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/14/2025
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.50
3/21/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
3/21/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
$265K197.24N/AN/A($0.20) per share-1.85
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A($0.17) per shareN/A
Exicure, Inc. stock logo
XCUR
Exicure
$500K136.47N/AN/A$1.75 per share6.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
-$26.24MN/A0.00N/AN/AN/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-$119.76M-$0.43N/AN/AN/AN/A-260.75%-76.04%8/6/2025 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/A
Exicure, Inc. stock logo
XCUR
Exicure
-$16.91M-$4.81N/AN/AN/A-190.90%-36.75%6/16/2025 (Estimated)

Latest ACER, APLT, XCUR, and SKYE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.31-$0.28+$0.03-$0.28N/AN/A
4/14/2025Q4 2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million
3/20/2025Q4 2024
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.30-$0.24+$0.06-$0.24N/AN/A
3/18/2025Q4 2024
Exicure, Inc. stock logo
XCUR
Exicure
N/A-$3.39N/A-$3.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
N/A
1.06
1.06
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
14.19
14.19
Exicure, Inc. stock logo
XCUR
Exicure
N/A
0.71
0.71

Institutional Ownership

CompanyInstitutional Ownership
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
98.31%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%
Exicure, Inc. stock logo
XCUR
Exicure
42.82%

Insider Ownership

CompanyInsider Ownership
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
20.20%
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
1.60%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
4.50%
Exicure, Inc. stock logo
XCUR
Exicure
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
3024.46 million19.52 millionNot Optionable
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
30141.58 million106.35 millionOptionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.98 million29.43 millionOptionable
Exicure, Inc. stock logo
XCUR
Exicure
506.32 million2.50 millionNot Optionable

Recent News About These Companies

Exicure announces issuance of new patent in Australia
Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm
Exicure announces purchase agreement with GPCR Therapeutics
When the Price of (XCUR) Talks, People Listen
When (XCUR) Moves Investors should Listen
(XCUR) Technical Pivots with Risk Controls

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acer Therapeutics stock logo

Acer Therapeutics NASDAQ:ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Applied Therapeutics stock logo

Applied Therapeutics NASDAQ:APLT

$0.37 +0.01 (+1.48%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$0.38 +0.01 (+1.57%)
As of 06/6/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$2.43 +0.28 (+13.02%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$2.38 -0.05 (-2.06%)
As of 06/6/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Exicure stock logo

Exicure NASDAQ:XCUR

$10.80 +0.90 (+9.09%)
Closing price 06/6/2025 03:59 PM Eastern
Extended Trading
$10.20 -0.60 (-5.59%)
As of 06/6/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.